Target type: biologicalprocess
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a 2,3,7,8-tetrachlorodibenzodioxine stimulus. [GO_REF:0000071, GOC:TermGenie, PMID:23196670]
Cellular response to 2,3,7,8-tetrachlorodibenzodioxine (TCDD) is a complex process involving multiple signaling pathways and molecular mechanisms. TCDD, a potent environmental toxin, exerts its effects primarily through the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor. Upon binding to TCDD, AhR undergoes a conformational change, dissociates from its chaperone proteins, and translocates to the nucleus. In the nucleus, AhR forms a heterodimer with the aryl hydrocarbon receptor nuclear translocator (ARNT), a process facilitated by the presence of co-chaperone proteins such as heat shock protein 90 (HSP90). This heterodimer binds to specific DNA sequences known as dioxin response elements (DREs) located in the regulatory regions of target genes.
The activation of AhR-ARNT complex leads to the transcriptional induction of a wide range of genes involved in various biological processes. Some of the key target genes include cytochrome P450 1A1 (CYP1A1), cytochrome P450 1B1 (CYP1B1), and glutathione S-transferase (GST), enzymes involved in detoxification and xenobiotic metabolism. The upregulation of these enzymes can enhance the metabolism of various compounds, potentially leading to increased oxidative stress and cellular damage.
TCDD exposure can also trigger a cascade of events that affect cell growth, differentiation, and apoptosis. It has been shown to induce cell cycle arrest, promote cell death, and alter cellular signaling pathways involved in inflammatory responses. The precise mechanisms underlying these effects are still being investigated, but it is believed that TCDD disrupts the balance of various intracellular signaling molecules, such as mitogen-activated protein kinases (MAPKs) and NF-κB, which are involved in cell survival and inflammatory responses.
Moreover, TCDD has been implicated in the development of various human diseases, including cancer, immune dysregulation, and reproductive toxicity. The specific molecular mechanisms involved in these disease processes are still being elucidated, but it is clear that TCDD can significantly disrupt the normal function of cells and tissues, leading to adverse health effects.
In summary, the cellular response to TCDD is a multifaceted process that involves the activation of the AhR signaling pathway, leading to the transcriptional induction of target genes, modulation of cellular signaling pathways, and potentially contributing to the development of various diseases. The precise molecular mechanisms involved are still being unraveled, but it is clear that TCDD can have significant impact on cell function and health.'
"
Protein | Definition | Taxonomy |
---|---|---|
Aryl hydrocarbon receptor | An aryl hydrocarbon receptor that is encoded in the genome of human. [PRO:DNx, UniProtKB:P35869] | Homo sapiens (human) |
cGMP-dependent 3',5'-cyclic phosphodiesterase | A cGMP-dependent 3,5-cyclic phosphodiesterase that is encoded in the genome of human. [PRO:DNx, UniProtKB:O00408] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
dibenzofuran | dibenzofuran : A mancude organic heterotricyclic parent that consists of a furan ring flanked by two benzene rings ortho-fused across the 2,3- and 4,5-positions. dibenzofurans : Any organic heterotricyclic compound based on a dibenzofuran skeleton and its substituted derivatives thereof. Dibenzofurans: Compounds that include the structure of dibenzofuran. | dibenzofurans; mancude organic heterotricyclic parent; polycyclic heteroarene | xenobiotic |
my 5445 | MY 5445: potential platelet aggregation inhibitor | pyridazines; ring assembly | |
3-methylcholanthrene | 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position. Methylcholanthrene: A carcinogen that is often used in experimental cancer studies. | ortho- and peri-fused polycyclic arene | aryl hydrocarbon receptor agonist; carcinogenic agent |
5,11-dihydroindolo[3,2-b]carbazole-12-carboxaldehyde | indolocarbazole | ||
theophylline | dimethylxanthine | adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent | |
benzo(a)pyrene | Benzo(a)pyrene: A potent mutagen and carcinogen. It is a public health concern because of its possible effects on industrial workers, as an environmental pollutant, an as a component of tobacco smoke. benzo[a]pyrene : An ortho- and peri-fused polycyclic arene consisting of five fused benzene rings. | ortho- and peri-fused polycyclic arene | carcinogenic agent; mouse metabolite |
beta-naphthoflavone | beta-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the f side of flavone. beta-Naphthoflavone: A polyaromatic hydrocarbon inducer of P4501A1 and P4501A2 cytochromes. (Proc Soc Exp Biol Med 1994 Dec:207(3):302-308) | extended flavonoid; naphtho-gamma-pyrone; organic heterotricyclic compound | aryl hydrocarbon receptor agonist |
bisacodyl | Bisacodyl: A diphenylmethane stimulant laxative used for the treatment of CONSTIPATION and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871) | diarylmethane | |
cilostamide | cilostamide: selective inhibitor of cyclic AMP phosphodiesterase & platelet aggregation; structure | quinolines | |
dipyridamole | dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots. Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol | adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent |
9-(2-hydroxy-3-nonyl)adenine | 9-(2-hydroxy-3-nonyl)adenine: specific inhibitor of adenosine deaminase | ||
amrinone | amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure. Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell. | bipyridines | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor |
1-methyl-3-isobutylxanthine | 1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES 3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively. | 3-isobutyl-1-methylxanthine | |
kynurenic acid | kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4. Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool. | monohydroxyquinoline; quinolinemonocarboxylic acid | G-protein-coupled receptor agonist; human metabolite; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist; Saccharomyces cerevisiae metabolite |
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source | chromones; morpholines; organochlorine compound | autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector |
milrinone | bipyridines; nitrile; pyridone | cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent | |
papaverine | papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum. Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels. | benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines | antispasmodic drug; vasodilator agent |
pentoxifylline | oxopurine | ||
proxyphylline | oxopurine | ||
pyrimethamine | Maloprim: contains above 2 cpds | aminopyrimidine; monochlorobenzenes | antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor |
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone | 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases. | methoxybenzenes | |
rolipram | pyrrolidin-2-ones | antidepressant; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | |
sulmazole | sulmazole : An imidazopyridine that is 1H-imidazo[4,5-b]pyridine which is substituted at position 2 by a 2-methoxy-4-(methylsulfinyl)phenyl group. An A1 adenosine receptor antagonist, it was formerly used as a cardiotonic agent. sulmazole: structure given in first source | imidazopyridine; sulfoxide | adenosine A1 receptor antagonist; cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor |
trequinsin | trequinsin: RN given refers to parent cpd; structure given in first source | pyridopyrimidine | |
zardaverine | zardaverine : A pyridazinone derivative in which pyridazin-3(2H)-one is substituted at C-6 with a 4-(difluoromethoxy)-3-methoxyphenyl group. It is a phosphodiesterase inhibitor, selective for PDE3 and 4. zardaverine: structure given in first source | organofluorine compound; pyridazinone | anti-asthmatic drug; bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; peripheral nervous system drug |
2-chloroadenosine | 5-chloroformycin A: structure given in first source | purine nucleoside | |
cycloguanil | cycloguanil : A triazine in which a 1,6-dihydro-1,3,5-triazine ring is substituted at N-1 by a 4-chlorophenyl group, at C-2 and -4 by amino groups and at C-6 by gem-dimethyl groups. A dihydrofolate reductase inhibitor, it is a metabolite of the antimalarial drug proguanil. cycloguanil: the active metabolite of proguanil; antifolate drug; structure in first source | triazines | antifolate; antiinfective agent; antimalarial; antiparasitic agent; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor |
indigo | hydroxyindoles | ||
2,3,7,8-tetrachlorodibenzodioxine | Tetrachlorodibenzodioxin: A mixture of isomers. | polychlorinated dibenzodioxine | |
2,4,2',4'-tetrachlorobiphenyl | 2,2',4,4'-tetrachlorobiphenyl : A tetrachlorobiphenyl that is biphenyl in which each of the phenyl groups is substituted at positions 2 and 4 by chlorines. 2,4,2',4'-tetrachlorobiphenyl: structure | dichlorobenzene; tetrachlorobiphenyl | |
octachlorodibenzo-4-dioxin | octachlorodibenzo-4-dioxin: RN given refers to unlabeled parent cpd | polychlorinated dibenzodioxine | |
cladribine | organochlorine compound; purine 2'-deoxyribonucleoside | antineoplastic agent; immunosuppressive agent | |
2-chlorodibenzofuran | 2-chlorodibenzofuran: structure | ||
1,2,3,4-tetrachlorodibenzodioxin | 1,2,3,4-tetrachlorodibenzodioxin: structure given in first source | polychlorinated dibenzodioxine | |
pcb 118 | dichlorobenzene; pentachlorobiphenyl; trichlorobenzene | ||
3,4,3',4'-tetrachlorobiphenyl | 3,3',4,4'-tetrachlorobiphenyl : A tetrachlorobiphenyl that is biphenyl in which the hydrogens at position 3 and 4 on each phenyl group are replaced by chlorines. 3,4,3',4'-tetrachlorobiphenyl: RN given refers to parent cpd | dichlorobenzene; tetrachlorobiphenyl | |
2,3,3',4,4'-pentachlorobiphenyl | dichlorobenzene; pentachlorobiphenyl; trichlorobenzene | ||
2,3,4,5-tetrachlorobiphenyl | tetrachlorobiphenyl : Any polychlorobiphenyl with molecular formula C12H6Cl4. | tetrachlorobenzene; tetrachlorobiphenyl | |
1,2,7,8-tetrachlorodibenzo-p-dioxin | 1,2,7,8-tetrachlorodibenzo-p-dioxin: structure in first source | ||
2,4,5,2',4',5'-hexachlorobiphenyl | hexachlorobiphenyl | ||
2,3,3',4,4',5-hexachlorobiphenyl | dichlorobenzene; hexachlorobiphenyl; tetrachlorobenzene | ||
2,8-dichlorodibenzo-4-dioxin | 2,8-dichlorodibenzo-4-dioxin: metabolite for 2,3,7,8-TCDD | ||
1,2,3,4,7,8-hexachlorodibenzodioxin | 1,2,3,4,7,8-hexachlorodibenzodioxin: structure given in first source | polychlorinated dibenzodioxine | |
1,2,4-trichlorodibenzo-1,4-dioxin | 1,2,4-trichlorodibenzo-1,4-dioxin: structure given in first source | ||
1,2,3,7,8-pentachlorodibenzo-p-dioxin | polychlorinated dibenzodioxine | ||
2,3,7,8-tetrabromodibenzo-4-dioxin | 2,3,7,8-tetrabromodibenzo-4-dioxin: structure given in first source 2,3,7,8-tetrabromodibenzodioxine : An organobromine compound that is dibenzodioxine carrying four bromo substituents at positions 2, 3, 7 and 8. | dibenzodioxine; organobromine compound | |
2,3,7,8-tetrachlorodibenzofuran | 2,3,7,8-tetrachlorodibenzofuran: toxic product which was generated in Italy due to an explosion in a plant manufacturing 2,4,5-trichlorophenol | polychlorinated dibenzofuran | |
2,3,4,7,8-pentachlorodibenzofuran | 2,3,4,7,8-pentachlorodibenzofuran: structure given in first source | polychlorinated dibenzofuran | |
1,2,3,7,8-pentachlorodibenzofuran | 1,2,3,7,8-pentachlorodibenzofuran: structure given in first source; RN given refers to parent cpd | polychlorinated dibenzofuran | |
1,2,3,4,7,8-hexachlorodibenzofuran | polychlorinated dibenzofuran | ||
2,3,4,4'5-pentachlorobiphenyl | monochlorobenzenes; pentachlorobiphenyl; tetrachlorobenzene | ||
enoximone | Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE. | aromatic ketone | |
imazodan | imazodan: RN & structure given in first source; | ||
3,4,5,3',4'-pentachlorobiphenyl | 3,3',4,4',5-pentachlorobiphenyl : A pentachlorobiphenyl in which the chlorines are located at the 3, 4, 5, 3', and 4' positions. | pentachlorobiphenyl; trichlorobenzene | |
bufrolin | bufrolin: inhibits the release of histamine; proposed for treatment of hay fever, asthma and skin allergies; minor descriptor (79-86); on line & INDEX MEDICUS search PHENANTHROLINES (79-86); RN given refers to parent cpd | ||
tadalafil | benzodioxoles; pyrazinopyridoindole | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent | |
6-methyl-1,3,8-trichlorodibenzofuran | 6-methyl-1,3,8-trichlorodibenzofuran: structure given in first source | ||
clofarabine | adenosines; organofluorine compound | antimetabolite; antineoplastic agent | |
9-(2-hydroxy-3-nonyl)adenine | (2R,3S)-EHNA : EHNA of absolute configuration 2R,3S. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase. | EHNA | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor |
9-(2-hydroxy-3-nonyl)adenine | (2S,3R)-EHNA : EHNA of absolute configuration 2S,3R. | EHNA | |
cilomilast | methoxybenzenes | ||
rp 73401 | piclamilast : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 3-(cyclopentyloxy)-4-methoxybenzoic acid with the primary amino group of 3,5-dichloropyridin-4-amine. piclamilast: an antiasthmatic agent and phosphodiesterase 4 inhibitor; structure in first source | aromatic ether; benzamides; chloropyridine; monocarboxylic acid amide | anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; phosphodiesterase IV inhibitor |
kynurenine | L-kynurenine : A kynurenine that has L configuration. | amino acid zwitterion; kynurenine; non-proteinogenic L-alpha-amino acid | human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite |
roflumilast | aromatic ether; benzamides; chloropyridine; cyclopropanes; organofluorine compound | anti-asthmatic drug; phosphodiesterase IV inhibitor | |
3-chlorodibenzofuran | 3-chlorodibenzofuran: structure given in first source | ||
4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2h)-pyridazinone | 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone: RN & structure given in first source | ||
kaempferol | 7-hydroxyflavonol; flavonols; tetrahydroxyflavone | antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite | |
1,3-dihydro-7,8-dimethyl-2h-imidazo(4,5-b)quinolin-2-one | 1,3-dihydro-7,8-dimethyl-2H-imidazo(4,5-b)quinolin-2-one: structure given in first source | ||
N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-4-quinazolinamine | quinazolines | ||
(2R,3S)-EHNA hydrochloride | (2R,3S)-EHNA hydrochloride : A hydrochloride salt obtained by reaction of (2R,3S)-EHNA with one equivalent of hydrochloric acid. Selective inhibitor of cGMP-stimulated phosphodiesterase (PDE2) (IC50 = 0.8 - 4 mM). Also a potent inhibitor of adenosine deaminase. | hydrochloride | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor |
pf 04217903 | quinolines | ||
an2728 | crisaborole : A member of the class of benzoxaboroles that is 5-hydroxy-1,3-dihydro-2,1-benzoxaborole in which the phenolic hydrogen has been replaced by a 4-cyanophenyl group. A phosphodiesterase 4 inhibitor that is used for treatment of mild to moderate atopic dermatitis in children and adults. crisaborole: NSAID, Dermatologic Agent; structure in first source | aromatic ether; benzoxaborole; nitrile | antipsoriatic; non-steroidal anti-inflammatory drug; phosphodiesterase IV inhibitor |
chf6001 | tanimilast: a phosphodiesterase-4 inhibitor; structure in first source | ||
sildenafil | sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position. | piperazines; pyrazolopyrimidine; sulfonamide | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent |
zaprinast | zaprinast: anaphylaxis inhibitor; structure | triazolopyrimidines | |
vardenafil | vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine. | imidazotriazine; N-alkylpiperazine; N-sulfonylpiperazine | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent |
bl 4162a | anagrelide : A 1,5-dihydroimidazo[2,1-]quinazoline having an oxo substituent at the 2-position and chloro substituents at the 6- and 7-positions. anagrelide: imidazoquinazoline derivative which lowers platelet count probably by inhibiting thrombopoiesis and reduces platelet aggregation; used for thrombocythemia; structure in first source | imidazoquinazoline | anticoagulant; antifibrinolytic drug; cardiovascular drug; platelet aggregation inhibitor |
7-bromoindirubin-3'-oxime | 7-bromoindirubin-3'-oxime: has mild protein kinase inhibitory activity; induces caspase-independent cell death; structure in first source | ||
bay 60-7550 |